Integra LifeSciences is a medical devices business based in the US. Integra LifeSciences shares (IART) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.75 – a decrease of 22.45% over the previous week. Integra LifeSciences employs 4,396 staff and has a trailing 12-month revenue of around $1.6 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $12.75 |
|---|---|
| 52-week range | $11.60 - $32.66 |
| 50-day moving average | $20.23 |
| 200-day moving average | $21.85 |
| Wall St. target price | $24.75 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.09 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.75 from 2025-05-06
| 1 week (2025-04-30) | -22.21% |
|---|---|
| 1 month (2025-04-08) | -29.44% |
| 3 months (2025-02-07) | -49.44% |
| 6 months (2024-11-08) | -48.55% |
| 1 year (2024-05-08) | -48.82% |
|---|---|
| 2 years (2023-05-05) | -74.87% |
| 3 years (2022-05-06) | 59.12 |
| 5 years (2020-05-07) | 51.18 |
Valuing Integra LifeSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Integra LifeSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Integra LifeSciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.851. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Integra LifeSciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Integra LifeSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $322.9 million.
The EBITDA is a measure of a Integra LifeSciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.6 billion |
|---|---|
| Operating margin TTM | 14.53% |
| Gross profit TTM | $959.1 million |
| Return on assets TTM | 2.91% |
| Return on equity TTM | -0.44% |
| Profit margin | -0.43% |
| Book value | $20.03 |
| Market Capitalization | $1.3 billion |
TTM: trailing 12 months
We're not expecting Integra LifeSciences to pay a dividend over the next 12 months.
Integra LifeSciences's shares were split on a 2:1 basis on 3 January 2017 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Integra LifeSciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Integra LifeSciences shares which in turn could have impacted Integra LifeSciences's share price.
Over the last 12 months, Integra LifeSciences's shares have ranged in value from as little as $11.6 up to $32.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Integra LifeSciences's is 1.245. This would suggest that Integra LifeSciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .